• Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Com­bi­na­tion with Anti-CD38 Monoclonal Anti­body Therapy for Multiple Myeloma
• Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Functional Components to Enhance Innate Immunity

San Diego, CA (Press Release) – Fate Thera­peutics, Inc. (NASDAQ: FATE), a clin­i­cal-stage bio­pharma­ceu­tical com­pany ded­i­cated to the de­vel­op­ment of pro­grammed cellular immuno­therapies for cancer and immune disorders, an­nounced to­day that the U.S. Food and Drug Admin­istra­tion (FDA) has cleared the Com­pany’s Inves­ti­ga­tional New Drug (IND) appli­ca­tion for FT538, the first CRISPR-edited, iPSC-derived cell ther­apy. FT538 is an off-the-shelf natural killer (NK) cell cancer immuno­therapy that is derived from a clonal master induced pluripotent stem cell (iPSC) line engi­neered with three functional components …